Gimoti denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gimoti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Gimoti as Non-Formulary

Gimoti (metoclopramide nasal spray) may sit outside BCBS's standard drug formulary, meaning the plan has not assigned it a covered tier. Non-formulary denials are not clinical judgments — they reflect the plan's negotiated pricing agreements and tier placement decisions. However, a non-formulary status does not mean you cannot get the drug covered; it means you must show that a formulary alternative is clinically inappropriate for you.

## Why This Denial Is Appealable

Every plan that covers prescription drugs must provide a formulary exception process. If your prescriber documents that a listed formulary alternative (such as oral metoclopramide) is contraindicated, has already failed, or is not clinically equivalent for your specific situation, the plan is required to consider covering the non-formulary drug. For a patient with gastroparesis whose nausea prevents reliable oral ingestion, the route-of-administration distinction is a legitimate clinical argument — not merely a preference.

## Your Federal Appeal Rights

• Formulary exception request: This is often a separate, faster track than a full internal appeal. Ask your prescriber to submit a formulary exception simultaneously with the prescription.
• Internal appeal (ERISA §503 / ACA §2719): If the exception is denied, you may escalate to a formal internal appeal. The denial letter must state the appeal deadline.
• External review: After exhausting internal steps (or if the plan fails to respond in time), you may request independent external review under ACA §2719. External reviewers can overturn non-formulary denials when the clinical record supports it. Standard turnaround is up to 45 days; expedited review is available for urgent cases.

## Documentation to Gather

• Formulary alternatives tried: For each formulary alternative the plan cites, provide prescription records and chart notes showing dates used, doses (from the prescribing record), and documented failure or intolerance.
• Clinical rationale for Gimoti specifically: A prescriber letter explaining why the nasal-spray route is medically necessary — for example, that oral absorption is unreliable due to the patient's level of gastroparesis-related nausea/vomiting.
• FDA prescribing information: Attach the current FDA-approved label for Gimoti as an exhibit to demonstrate the approved indication and the clinical basis for route selection.
• Relevant guideline citation: Ask your prescriber to reference the applicable professional society guideline (e.g., the American Neurogastroenterology and Motility Society) generically, without relying on specific numbers that may not match the plan's own thresholds.

## Criteria-Mapping Structure

Request a written copy of BCBS's formulary exception criteria for Gimoti. Build a table addressing each requirement:

| Exception Criterion | Your Evidence | |---|---| | Formulary drug(s) previously tried | [drug names, dates, prescribing records] | | Reason formulary alternative is inadequate | [chart documentation of failure or absorption concern] | | Diagnosis confirmation | [gastric-emptying study and treating physician note] | | Prescriber attestation of medical necessity | [signed prescriber letter] |

A complete, organized submission that directly addresses each criterion is significantly more likely to succeed than a general appeal narrative.